The nonsteroidal anti-inflammatory drug sulindac reverses obesity-driven immunosuppression and triple-negative breast cancer progression.

Bibliographic Details
Published in:Breast Cancer Research Vol. 27; no. 1; pp. 1 - 17
Main Authors: Coleman, Michael F., McDonell, Shannon B., Eisenbeis, Lydia K., Devericks, Emily N., Chandi, Jobin, Dave, Om, Pearce, Jane B., Wang, Sylvia, Cody, Morgan, Bustamante-Marin, Ximena M., Glenny, Elaine M., Rezeli, Erika T., Cozzo, Alyssa J., O'Flanagan, Ciara H., Bathon, Brooke E., Shaikh, Saame Raza, Milne, Ginger L., Wendt, Michael K., Lanman, Nadia A., Teegarden, Dorothy
Format: Journal Article
Published: BioMed Central 10/24/2025
Online Access:View this record in EBSCOhost